NRX Pharmaceuticals (NRXP) Net Margin (2025 - 2026)
NRX Pharmaceuticals' (NRXP) quarterly Net Margin came in at 465.36% in Q1 2026, up 3.5% on a QoQ basis from 482.25% in Q4 2025.
NRX Pharmaceuticals (NRXP) Net Margin (2025 - 2026) Analysis & Trends
NRX Pharmaceuticals (NRXP) has 2 years of Net Margin data on file, last reported at 465.36% in Q1 2026.
- On a quarterly basis, Net Margin changed N/A year-over-year to 465.36% in Q1 2026; TTM through Mar 2026 was 787.47%, a N/A change from a year earlier, with the FY2025 full-year figure at 5617.67%, changed N/A from the prior year.
- Net Margin for Q1 2026 stood at 465.36%, up from 482.25% in the prior quarter.
- Over the last five years, Net Margin for NRXP reached as high as 465.36% in Q1 2026 and fell as low as 2105.5% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 15.02% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 34.53% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 20.17% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 30.33% |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | NRX Pharmaceuticals | 117.34 Mn | 110.64 Mn | 437,000.00 | -465.36% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -465.36% |
| Dec 31, 2025 | -482.25% |
| Sep 30, 2025 | -2,105.50% |